Related Experiment Videos
Neonatal screening for cystic fibrosis
F Bowling1, G Cleghorn, A Chester
1Neonatal Screening Laboratory, State Department of Health, Royal Children's Hospital, Brisbane, Australia.
Archives of Disease in Childhood
|February 1, 1988
Summary
Early screening for cystic fibrosis using an improved immunoreactive trypsin assay led to fewer chest infections and better weight gain in newborns. This suggests neonatal screening significantly reduces early disease severity.
Area of Science:
- Pediatrics
- Medical Diagnostics
- Genetics
Background:
- Cystic fibrosis (CF) is a genetic disorder affecting multiple organs.
- Early detection of CF is crucial for timely intervention and improved outcomes.
- Neonatal screening aims to identify CF in infants before symptoms manifest.
Purpose of the Study:
- To evaluate the impact of an improved neonatal screening assay for immunoreactive trypsin (IRT) on early cystic fibrosis morbidity.
- To compare clinical outcomes between a screened and an unscreened group of patients with cystic fibrosis.
Main Methods:
- A comparative study involving two groups of patients diagnosed with cystic fibrosis.
- One group was identified through an enhanced neonatal screening assay for IRT.
- The other group served as an unscreened control.
Main Results:
- The screened group exhibited a lower incidence of chest infections requiring medical treatment compared to the unscreened group.
- Infants in the screened group demonstrated superior weight gain.
- These findings indicate a reduction in early cystic fibrosis-related morbidity.
Conclusions:
- Improved neonatal screening for cystic fibrosis, utilizing an enhanced IRT assay, is effective in reducing early disease complications.
- Early diagnosis through neonatal screening positively impacts key indicators of infant health, such as respiratory infections and growth.